Previous 10 | Next 10 |
-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest Agreement with HealthCare Royalty -- -- Health Canada grants Priority Review sta...
Looking for stocks that are beating the market in 2022? Our roundtable has three healthcare names that are killing it right now: Shockwave Medical (NASDAQ: SWAV) , Axsome Therapeutics (NASDAQ: AXSM) , and Rhythm Pharmaceuticals (NASDAQ: RYTM) . Read more to find out ...
Rising interest rates, sky-high inflation, and geopolitical turmoil have all conspired against U.S. stock markets this year. Despite a bear market rally over the past seven weeks, every major U.S. stock exchange is still down big for the year. For instance, the S&P 500 is curren...
The shares of Rhythm Pharmaceuticals ( NASDAQ: RYTM ) jumped ~14% in the morning hours Monday after Goldman Sachs upgraded the commercial-stage biotech to Buy from Neutral and raised the price target to $28 from $6, citing the potential of its weight loss therapy setmelanoti...
BofA analyst Tazeen Ahmad upgraded Rhythm Pharmaceuticals ( RYTM ) to Neutral from Underperform with a price target of $20, up from $8. The company is seeing a strong early BBS launch performance, Ahmad tells investors following the company's Q2 report. However, Ahmad awaits f...
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathw...
Shares of Rhythm Pharmaceuticals (NASDAQ: RYTM) are surging Tuesday afternoon. As of 2:48 p.m. ET, the small-cap biotech's stock was up by a healthy 14.4% on sky-high volume. What's sparking this double-digit move higher? Prior to Tuesday's opening bell, Rhythm Pharmaceuticals a...
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2022 Results Earnings Conference Call August 2, 2022, 08:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer ...
Rhythm Pharmaceuticals ( NASDAQ: RYTM ) is trading 21% higher after the company posted narrower-than-expected Q2 loss, helped by sales of its genetic disorder drug, Imcivree and license revenue. The company posted Q2 GAAP EPS of -$0.89, which beat estimate...
Gainers: Quoin Pharmaceuticals ( QNRX ) +45% . Context Therapeutics CNTX +13% . Rhythm Pharmaceuticals RYTM +13% . Harmony Biosciences HRMY +10% . Nautilus Biotechnology NAUT +9% . Losers: Ontrak OTRK -43% . Phathom Pharmaceutical...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...